AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02714946 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Laser Ablation
Description: Single session with standardized approach: One or two fibers will be used for treatments including one to three illuminations with a fixed output power of 3 W, using the pullback technique. Energy for each emission will be 1200-1800J based on nodule volume. The treatment is performed under local anesthesia and conscious sedation.
Study NCT02714946 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Radiofrequency Ablation
Description: Single session with standardized approach: A radiofrequency generator and a 17-gauge, 15-cm electrode with a 1-cm active tip will be used. A transisthmic approach along the short axis of the nodule will be used and the nodules will be managed with the moving-shot technique. 60 W of radiofrequency outpower will be used for all nodules. The treatment is performed under local anesthesia and conscious sedation
Study NCT04170452 — intervention group
Intervention type: PROCEDURE
Intervention: liver biopsy
Description: Pre-procedure assessment of the liver with ultrasound should be performed for planning positioning and needle entrance point. Supine, oblique, or total left lateral decubitus are the possible positioning of the patient - it is important to make sure that the patient is comfortable and can remain still in that position. Assessing if the procedure will be performed under breath held and practice this with the patient. Marking of the entrance point on the skin is advised to aid the skin cleaning and dressing. A time-out should be performed by this stage. Skin site is prepped and draped to ensure asepsis. Ocal anaesthesia is infiltrated under the skin abdominal wall/intercostal space until the liver capsule. Entrance point is created with a scalpel. Using the freehand technique the needle is advanced under ultrasound guidance during the entire course of the biopsy. The needle tip must always cross the capsule prior to deploying the cutting device.
Study NCT01418768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inpatient rehabiliation
Description: inpatient, multimodal, individual workout including endurance training, strength training, coordination training etc. for three weeks.
Study NCT00754767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine L-tartrate
Description: Given orally
Study NCT02624297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: The patients will be submitted to four months of aerobic exercise training, three time a week.
Study NCT02764853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Intervention (STEP-AD)
Description: This experimental intervention will consist of 10 sessions- 1 session of Lifesteps (problem solving for medication adherence) and 9 sessions of an intervention specifically tailored for Black women living with HIV to address trauma/abuse, racial discrimination, HIV stigma, and gender roles expectations in order to improve health outcomes (e.g., medication adherence, viral load), increase resiliency, and enhance adaptive coping strategies.
Study NCT02764853 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual (E-TAU)
Description: Participants assigned to the E-TAU condition will receive 1 session of Lifesteps (problem solving for medication adherence) and appropriate services and referrals as needed
Study NCT00521911 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Study NCT01275547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: s-ketamine & midazolam
Description: s-ketamine 6 mg intranasal midazolam 0.75 mg intranasal
Study NCT01275547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine PCA
Description: 2 mg Morphine i.v. all 12 minutes as a patient controlled system
Study NCT04016584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Pueblo
Description: These adults will receive diabetes education, the Diabetes Pueblo Program, and will complete Curriculum (A), Diabetes Fundamentals, and Curriculum (B), Insulin Success.
Study NCT00754767 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT01570725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality exposure
Description: The Green Valley, a non interactive, relaxing environment showing a mountain landscape around a calm lake is presented to the patient together with the relaxing music and soft sounds (birds' songs, the water flowing, etc). Having the impression of walking around the lake, patients can observe the nature and virtually seat on a comfortable deck chair, in order to become easily relaxed.~Patients were exposed to the virtual environment for the entire length of the operation.
Study NCT01570725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music only
Description: A relaxing music and nature sounds have been used to provide a calm atmosphere and reduce stress. In the Music group it was provided to the patients through earphones with no visual stimulation.
Study NCT03103750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Magnetic resonance imaging (MRI) scans (3 T) will be collected in each subject for the purposes of excluding participants with anatomical abnormalities and anatomically co-registering PET and MRI for image analysis
Study NCT03103750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHNO
Description: Used as a tracer for in vivo imaging.
Study NCT03103750 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcitriol
Description: three 0.5 mcg capsules
Study NCT03103750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: three 0.5 mcg capsules
Study NCT03103750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high-resolution research tomography
Description: A functional imaging technique that is used to observe metabolic processes in the body.
Study NCT03103750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextro Amphetamine
Description: Dexedrine 0.3 mg/kg, to a maximum dose of 30 mg
Study NCT03531957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002
Description: Daily dose of ASN002 for 12 weeks
Study NCT03531957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo of ASN002 for 12 weeks
Study NCT02263339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Each subject will exercise 30 minutes per session, four times per week for 8 weeks at the OHSU Human Performance Laboratory (HPL). Choice of treadmill or cycle ergometer for each subject will be made based on subject ability by the HPL staff and maintained for the duration of the study. Exercise intensity will be determined by training heart rate to be provided to the subject based on the anaerobic threshold during initial stress test. Throughout the study, patients will be instructed not to alter their diet or baseline level of activity.
Study NCT02263339 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Each subject will follow a self-guided stretching program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.
Study NCT02263339 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise- Healthy Subjects
Description: Each subject will follow a self-guided aerobic exercise program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.
Study NCT03780517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172738
Description: Oral capsules
Study NCT02332915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sound Production Treatment (SPT)
Description: SPT is a behavioral treatment for acquired apraxia of speech. It involves verbal modeling of target words by the clinician, simultaneous productions, articulatory placement instructions, and repeated practice. Treatment is administered in the context of an hierarchy.
Study NCT03927729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: Pain will be treated with inhaled methoxyflurane (Penthrox®).
Study NCT00576498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NBI-AFI imaging
Description: Narrow Band Imaging- Patients will be evaluated with a standard magnification endoscope (Olympus GIF Q240Z, 115x or GIF-H180 or equivalent) using a NBI light source.Target biopsies with standard biopsy forceps will be obtained from the different visualized patterns in separate jars.~Autofluorescence Imaging- Patients will be evaluated using a prototype autofluorescence endoscope (Olympus, Tokyo, Japan; excitation 395-475 nm, fluorescence detection 490-625 nm, red reflectance 600-620 nm and green reflectance 540-560 nm).In this system, normal squamous and non-dysplastic BE appears green while the dysplastic areas appear magenta/purplish. Targeted biopsies will be obtained from the areas with abnormal fluorescence.
Study NCT00576498 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Endoscopy
Description: Standard Endoscopy- Patients will undergo EGD with biopsies using a standard diagnostic video endoscope (Olympus, GIF 140 or 160) using the Seattle protocol - 4 quadrant biopsies using standard biopsy forceps every 2 cms; stored in separate jars.
Study NCT01920139 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fine needle aspiration and core biopsy of lymph node
Description: Ultrasound guided fine needle aspiration of an abnormal lymph node followed by ultrasound guided core biopsy of the same node followed by clip placement into the node.
Study NCT00274781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Arsenic trioxide will be administered at a dose of 0.25 mg/kg/day IV over 1-2 hours for 5 consecutive days during the first week. Subsequently, arsenic trioxide will be given at a dose of 0.25mg/kg/day twice a week for 11 additional weeks (weeks 2-12).
Study NCT00274781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin
Description: Gemtuzumab ozogamicin consists of a 2 hr infusion at a dose of 3mg/m2 on day 8 of each 12-week cycle. Gemtuzumab ozogamicin should be administered at a minimum of one hour after the completion of the arsenic trioxide infusion
Study NCT01028586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Safinamide, MAO-B inhibitor
Description: Safinamide, MAO-B inhibitor 50 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
Study NCT01888887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil Daily Facial Cleanser
Study NCT01992978 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency-assisted Hepatectomy
Description: Radiofrequency-assisted resection: separating the tumor from liver by using the probe of radiofrequency to block the arterial and vessels before parenchymal transection.
Study NCT01920139 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Axillary surgery
Description: Patients underwent axillary node dissection or excision of setinel axillary nodes at the time of surgical treatment of their breast cancer.
Study NCT01920139 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Titanium marker
Description: A titanium marker was deposited into the lymph node that was percutaneously biopsied , immediately after the last tissue sample obtained.
Study NCT02675517 — intervention group
Intervention type: DRUG
Intervention: Spiolto Respimat
Description: Tiotropium bromide + Olodaterol
Study NCT04012411 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brain MRI
Description: Multimodal brain MRI: volumetry, diffusion tensor, functional rest MRI
Study NCT04012411 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Punction
Description: Analysis of BDNF, Tau, NFL and TrkB in cerebrospinal fluid
Study NCT04012411 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: Analysis of BDNF, Tau, NFL, and Val66Met polymorphism
Study NCT04012411 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive evaluation
Description: Symbol Digit Modality Test (SDMT), Stroop test, Trail Making Test, Empan
Study NCT04165265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Constant-Care
Description: Constant-Care (CC) (https://ibd.constant-care.com) is a web-application and contains an education and a disease monitoring package. An algorithm is established in the disease monitoring package, which consist of two variables; fecal calprotectin (FC) and a disease activity questionnaire (validated), Simple Clinical Colitis Activity index (SCCAI) for UC. The FC is obtained through CalproSmart app (it only takes 18 min) and the questionnaire is filled out in CC. Afterwards, the data are analyzed by CC and presented in a Total Inflammatory Burden Score (TIBS) as well as a visual traffic light of disease for the patients
Study NCT03000452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DARATUMUMAB
Description: DARATUMUMAB
Study NCT03000452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DURVALUMAB
Description: DURVALUMAB
Study NCT03446170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graphic cigarette warning labels, plain packaging
Description: This study tests the effects of graphic cigarette warning labels that include pictures and text, and plain or standardized packaging
Study NCT01992978 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Hepatectomy
Description: Hepatectomy was conducted without RF assisted during parenchymal transection. Separating and dissecting the tumor with the routine clamp-crushing technical.
Study NCT01028586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Safinamide, MAO-B inhibitor
Description: Safinamide, MAO-B inhibitor 100 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
Study NCT01028586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablets
Study NCT01532635 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: TBI twice daily for 4 days and occurs 6 to 9 days prior to the transplant. Total radiation dose is 12 Gy.
Study NCT01532635 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion (DLI)
Description: DLI given 6 days prior to transplant (HSCT).
Study NCT01532635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
Study NCT01532635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus is started the day before the transplant and stops a few months after transplant.
Study NCT01532635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: MMF is started the day before transplant and stops a few weeks after transplant.
Study NCT01532635 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplant (HSCT)
Description: CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed using donor cells from two related donors.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem cells.
Study NCT00955448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIS mesh (Cook Medical)
Description: Anterior prolapse repair will be reinforced using surgical mesh made from porcine small intestine mucosa (Cook Medical)
Study NCT00955448 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior prolapse repair
Description: Anterior prolapse repair will be conducted without using mesh reinforcement
Study NCT00955448 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior prolapse repair
Description: Anterior prolapse repair will be conducted without using mesh reinforcement
Study NCT01386853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: 2 mg QD
Study NCT01386853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 10 mg QD
Study NCT04371224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Liposomal Injection [Onivyde]
Description: both arm
Study NCT03997734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: single and repeated dosing
Study NCT04371224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposomal Injection [Onivyde]
Description: both arm
Study NCT04371224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: NaliCap
Study NCT04038658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move-It
Study NCT00372515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: On days 1-14 gefitinib will be taken orally daily at either 750, 1000, or 1250mg (depends upon when subject entered trial). If medication is tolerated well, subject will take 500mg daily on days 15-28 of each 28-day cycle. Cycles (higher dose followed by lower dose) will be repeated as long as subject's cancer does not worsen and they do not experience any serious side effects.
Study NCT04367454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of Personal Protective Equipment
Description: As described in the arm descriptions
Study NCT00558493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine
Description: clevudine 30 mg qd for 24 seeks
Study NCT03905174 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: custom made device
Description: surgical intervention to place custom made orthopaedic device
Study NCT01064284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLASMA DERIVED Factor VIII
Description: Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
Study NCT01064284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant FVIII
Description: Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
Study NCT03555097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: incremental pressure support
Description: Inspiratory positive airway pressure (IPAP) gradually increases from 10 to 24 cm water column (cmH2O) with 2 water column (cmH2O) increments. The expiratory positive airway pressure (EPAP) remains 4 water column (cmH2O), and each pressure level is maintained for 5 to 10 minutes.
Study NCT06069271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kettlebell swing
Description: The intervention group completed two-handed Russian KBSs using an interval training protocol outlined by Jay et al.10 involving 30 seconds of work followed by 30 seconds of rest for 10 total intervals. Prior to completing the intervention, participants completed a general warmup consisting of 10 non-weighted squats, 10 non-weighted dead-lifts, and 10 dowel rod shoulder flexion repetitions. Participants were instructed to perform all warm-up activities at an intensity of 70% of maximal effort using a Rate of Perceived Exertion scale(RPE).
Study NCT03406052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-Assisted MB-CBT
Description: Experimental subjects will receive a mindfulness-based CBT online software program workbook (in collaboration with Nex J Systems, Inc.) accessible online. Exposure to and interaction with the online workbook is combined with health coaching (duration of 24 total hours) primarily delivered in phone and software interactions. In addition, each participant will be given a Fitbit-HR Charge, a wearable bracelet that assesses physical steps and 24 hour heart rate in 5 second (averaged) durations (with related access to software that permits daily tracking).
Study NCT01659541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expiratory muscle stimulator
Description: The expiratory muscle stimulator consists of two small electrodes (wire leads) implanted on the surface of the spinal cord on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
Study NCT06740175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral optoacoustic tomography
Description: If patients are willing to participate in this study, they are imaged with the multispectral optoacoustic tomography device (MSOT Acuity Echo) at the department of nuclear medicine and molecular imaging. The imaging procedure takes 15 minutes at most.
Study NCT02628665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: photosensitizer(photofrin)
Description: photosensitizer(photofrin): 2mg/kg
Study NCT02628665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: photosensitizer(photofrin)
Description: photosensitizer(photofrin): 2mg/kg
Study NCT02628665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 630 nm laser irradiation (DIOMED)
Description: 630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds.